(Q53167532)

12 May 2018

title

Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. (English)

1 reference

12 May 2018

0 references

1 reference

1 reference

1 reference

A J Colquhoun

1 reference

12 May 2018

N A Venier

1 reference

12 May 2018

A D Vandersluis

1 reference

12 May 2018

R Besla

1 reference

12 May 2018

L M Sugar

1 reference

12 May 2018

A Kiss

1 reference

12 May 2018

N E Fleshner

1 reference

12 May 2018

M Pollak

1 reference

12 May 2018

L H Klotz

1 reference

12 May 2018

V Venkateswaran

1 reference

12 May 2018

publication date

22 May 2012

1 reference

12 May 2018

Prostate Cancer and Prostatic Diseases

published in

1 reference

12 May 2018

volume

1 reference

12 May 2018

issue

1 reference

12 May 2018

page(s)

346-352

1 reference

12 May 2018

Prevalence of overweight and obesity in the United States, 1999-2004

cites work

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Body size and composition and risk of rectal cancer (Australia).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Trends in the incidence of type 2 diabetes mellitus from the 1970s to the 1990s: the Framingham Heart Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

In vitro metformin anti-neoplastic activity in epithelial ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Multiple G1 regulatory elements control the androgen-dependent proliferation of prostatic carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Effects of the dual 5 alpha-reductase inhibitor dutasteride on apoptosis in primary cultures of prostate cancer epithelial cells and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Novel assay of metformin levels in patients with type 2 diabetes and varying levels of renal function: clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Obesity, Diabetes, and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Anthropometrics and Prostate Cancer Risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FPCAN.2012.16

31 March 2020

Identifiers

DOI

10.1038/PCAN.2012.16

1 reference

12 May 2018

1 reference

12 May 2018